Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.54 |
| ▸ | DAO | P14920 | 2/20 | 0.50 |
| ▸ | PARP1 | P09874 | 3/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | PDE6D | O43924 | 1/20 | 0.38 |
| ▸ | PDE8A | O60658 | 1/20 | 0.38 |
| ▸ | PDE5A | O76074 | 1/20 | 0.38 |
| ▸ | PDE9A | O76083 | 1/20 | 0.38 |
| ▸ | PDE8B | O95263 | 1/20 | 0.38 |
| ▸ | PDE6A | P16499 | 1/20 | 0.38 |
| ▸ | PDE6G | P18545 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE6B | P35913 | 1/20 | 0.38 |
| ▸ | PDE6C | P51160 | 1/20 | 0.38 |
| ▸ | PDE1A | P54750 | 1/20 | 0.38 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL167012 | 0.98 | ATAD2 (0.56) | ATAD2DAOPARP1PDE2APDE6D | |
| SCHEMBL27791126 | 0.87 | ATAD2 (0.46) | ATAD2DAOPARP1PDE2APDE6D | |
| Isoxazole SCHEMBL29144694 | 0.84 | ATAD2 (0.44) | ATAD2DAOPARP1PDE2APDE6D | |
| Aminothiazole SCHEMBL29250377 | 0.83 | ATAD2 (0.43) | ATAD2DAOPARP1FGFR1HRH4 | |
| Trifluoromethanesulfonic Acid SCHEMBL5258752 | 0.83 | DAO (0.43) | ATAD2DAOPARP1FGFR1HRH4 | |
| Quinoline SCHEMBL18171691 | 0.78 | ALDH1A1 (0.55) | ATAD2DAOPARP1FGFR1ALDH1A1 | |
| SCHEMBL18035168 | 0.73 | ATAD2 (0.35) | ATAD2DAOPDE3BPDE3A | |
| SCHEMBL29937409 | 0.73 | ATAD2 (0.35) | ATAD2DAOPDE3BPDE3A | |
| SCHEMBL31042178 | 0.72 | DAO (0.53) | ATAD2DAOPARP1PDE2APDE6D | |
| SCHEMBL586351 | 0.72 | DAO (0.53) | ATAD2DAOPARP1PDE2APDE6D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10443039-B2 | Inhibition of dendritic cell-driven regulatory T cell activation and potentiation of tumor antigen-specific T cell responses by interleukin-15 and MAP kinase inhibitor | BIOVENTURES, LLC (US) | 2019-10-15 | — | — | US | disclosed |
| EP-2205252-B1 | INHIBITION OF DENDRITIC CELL-DRIVEN REGULATORY T CELL ACTIVATION AND POTENTIATION OF TUMOR ANTIGEN-SPECIFIC T CELL RESPONSES BY INTERLEUKIN-15 AND MAP KINASE INHIBITOR | UNIV ARKANSAS (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20140037579-A1 | Inhibition of Dendritic Cell-Driven Regulatory T Cell Activation and Potentiation of Tumor Antigen-Specific T Cell Responses by Interleukin-15 and MAP Kinase Inhibitor | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2014-02-06 | — | — | US | disclosed |
| US-8546137-B2 | Inhibition of dendritic cell-driven regulatory T cell activation and potentiation of tumor antigen-specific T cell responses by interleukin-15 and MAP kinase inhibitor | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2013-10-01 | — | — | US | disclosed |
| EP-2205252-A2 | INHIBITION OF DENDRITIC CELL-DRIVEN REGULATORY T CELL ACTIVATION AND POTENTIATION OF TUMOR ANTIGEN-SPECIFIC T CELL RESPONSES BY INTERLEUKIN-15 AND MAP KINASE INHIBITOR | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2010-07-14 | — | — | EP | disclosed |
| US-20090136447-A1 | Inhibition of dendritic cell-driven regulatory T cell activation and potentiation of tumor antigen-specific T cell responses by interleukin-15 and MAP kinase inhibitor | BIOVENTURES, LLC | 2009-05-28 | — | — | US | disclosed |
| WO-2009042215-A2 | INHIBITION OF DENDRITIC CELL-DRIVEN REGULATORY T CELL ACTIVATION AND POTENTIATION OF TUMOR ANTIGEN-SPECIFIC T CELL RESPONSES BY INTERLEUKIN-15 AND MAP KINASE INHIBITOR | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2009-04-02 | — | — | WO | disclosed |